1. Biggs JM, Morgan JA, Lardieri AB, et al. Abuse and misuse of selected dietary supplements among adolescents: a look at poison center data. J Pediatr Pharmacol Ther. 2017;22(6):385-393.

2. Rao N, Spiller HA, Michaels NL, et al. An increase in dietary supplement exposures reported to U.S. poison control centers. J Med Toxicol. 2017;13:227-237.

3. Smith SM, Dart RC, Katz NP, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain. 2013;154(11):2287-2296.

4. Gennaro A. Remington: The Science and Practice of Pharmacy. 19th ed. St. Louis, MO: Lippincott Williams & Wilkins; 1996.

5. California Department of Public Health. Stimulants. Available at https://www.cdph.ca.gov/Programs/CCDPHP/sapb/Pages/Stimulants. Last accessed April 17, 2025.

6. Archer JR, Dargan PI, Lostia AM, et al. Running an unknown risk: a marathon death associated with the use of 1,3-dimethylamylamine (DMAA). Drug Test Anal. 2015;7(5):433-438.

7. Di Lorenzo C, Moro E, Dos Santos A, Uberti F, Restani P. Could 1,3 dimethylamylamine (DMAA) in food supplements have a natural origin? Drug Test Anal. 2013;5(2):116-121

8. Vorce SP, Holler JM, Cawrse BM, Magluilo J. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines.J Anal Toxicol. 2011;35:183-187

9. Gee P, Jackson S, Easton J. Another bitter pill: a case of toxicity from DMAA party pills. N Z Med J. 2010;123:124-127.

10. TRC Healthcare. 1,3-DMAA. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=1258. Last accessed April 15, 2025.

11. Health Canada. Classification of 1,3-dimethylamylamine (DMAA). Available at https://www.scribd.com/document/82744576/DMAA-Health-Canada-2011. Last accessed October 21, 2025.

12. Lammie J. Report Of The Department Of Defense 1,3 Dimethylamylamine (DMAA) Safety Review Panel. Available at https://docslib.org/doc/2302579/report-of-the-department-of-defense-1-3-dimethylamylamine-dmaa-safety-review-panel. Last accessed October 21, 2025.

13. The World Anti-Doping Code. The 2025 Prohibited List International Standard. Available at https://www.wada-ama.org/sites/default/files/2024-09/2025list_en_final_clean_12_september_2024.pdf. Last accessed October 21, 2025.

14. Eliason MJ, Eichner A, Cancio A, Bestervelt L, Adams BD, Deuster PA. Case reports: death of active duty soldiers following ingestion of dietary supplements containing 1,3-dimethylamylamine (DMAA). Mil Med. 2012;177(12):1455-1459.

15. Pawar RS, Sagi S, Leontyev D. Analysis of bitter orange dietary supplements for natural and synthetic phenethylamines by LC-MS/MS. Drug Test Anal. 2020;12(9):1241-1251.

16. Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med. 2004;229:698-704.

17. Zhao J, Wang M, Avula B, Khan IA. Detection and quantification of phenethylamines in sports dietary supplements by NMR approach. J Pharm Biomed Anal. 2018;151:347-355.

18. Thevis M, Koch A, Sigmund G, Thomas A, Schänzer W. Analysis of octopamine in human doping control samples. Biomed Chromatogr. 2012;26(5):610-615.

19. National Collegiate Athletic Association. NCAA Banned-Drug Classes 2005–2006. Available at http://www1.ncaa.org/membership/ed_outreach/health-safety/drug_testing/banned_drug_classes.pdf. Last accessed October 21, 2025.

20. TRC Healthcare. Bitter Orange. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=976. Last accessed October 21, 2025 .

21. TRC Healthcare. Caffeine. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=979. Last accessed October 21, 2025.

22. Suleman A, Siddiqui NH. Haemodynamic and cardiovascular effects of caffeine. Available at http://www.priory.com/pharmol/caffeine.htm. Last accessed October 21, 2025.

23. Heckman MA, Weil J,Gonzalez de Mejia E. Caffeine (1, 3, 7-trimethylxanthine) in foods: a comprehensive review on consumption, functionality, safety, and regulatory matters. J Food Sci. 2010;75(3):R77-R87.

24. McCusker RR, Goldberger BA, Cone EJ. Caffeine content of energy drinks, carbonated sodas, and other beverages. J Anal Toxicol. 2006;30(2):112-114.

25. Temple J, Bernard C, Lipshultaz S, et al. The safety of ingested caffeine: a comprehensive review. Front Psychiatry. 2017;8(80).

26. Banned Substances Control Group. Caffeine and Guarana in NCAA Drug Testing: Key Facts and Guidelines. Available at https://www.bscg.org/caffeine-and-guarana-ncaa-drug-testing-factsheet. Last accessed October 21, 2025.

27. National Collegiate Athletic Association. NCAA Banned Substances. Available at: https://www.ncaa.org/sports/2015/6/10/ncaa-banned-substances.aspx. Last accessed October 21, 2025.

28. United States Olympic Committee Sport Nutrition Team. Caffeine Factsheet. Available at https;//www.northwestern.edu/sportsmedicine/images/caffeine-fact-sheet-2015.pdf. Last accessed October 21, 2025.

29. Guest NS, VanDusseldorp TA, Nelson MT, Grgic J, Schoenfeld BJ, Jenkins NDM, et al. International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr. 2021;18(1):1.

30. U.S. Food and Drug Administration. FDA Takes Step to Protect Consumers Against Dietary Supplements Containing Dangerously High Levels of Extremely Concentrated or Pure Caffeine. Available at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604485.htm. Last accessed October 21, 2025.

31. Wikoff D, Welsh BT, Henderson R, et al. Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children. Food Chem Toxicol. 2017;109:585-648.

32. Institute of Medicine Committee on Military Nutrition Research. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington, DC: National Academies Press; 2001.

33. Graves JM, Dilley JA, Terpak L, et al. Kratom exposures among older adults reported to U.S. poison centers, 2014–2019. J Am Geriatr Soc. 2021;69(8):2176-2184.

34. Jagim AR, Harty PS, Fischer KM, Kerksick CM, Erickson JL. Adverse events reported to the United States Food and Drug Administration related to caffeine-containing products. Mayo Clin Proc. 2020;95(8):1594-1603.

35. Jantos R, Stein KM, Flechtenmacher C, Skopp G. A fatal case involving a caffeine-containing fat burner. Drug Test Anal. 2013;5(9-10):773-776.

36. Avci S, Sarikaya R, Büyükcam F. Death of a young man after overuse of energy drink. Am J Emerg Med. 2013;31(11):1624.e3-e4.

37. Kim BS, Song MY, Kim H. The anti-obesity effect of Ephedra sinica through modulation of gut microbiota in obese Korean women.J Ethnopharmacol. 2014;152(3):532-539.

38. Lai S, Yu C, Dennehy CE, Tsourounis C, Lee KP. Online marketing of Ephedra weight loss supplements: labeling and marketing compliance with the U.S. Food and Drug Administration ban on Ephedra. J Altern Complement Med. 2021;27(9):796-802.

39. TRC Healthcare. Ephedra. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=847. Last accessed October 21, 2025.

40. U.S. Food and Drug Administration. FDA Announces the Availability of New Ephedrine and "Street Drug Alternative" Documents. Available at https://www3.scienceblog.com/community/older/archives/M/1/fda0617.htm. Last accessed October 21, 2025.

41. U.S. Food and Drug Administration, HHS. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk; final rule. Fed Regist. 2004;69:6787-6854.

42. Yahagi T, Atsumi T, Mano S, et al. Quality evaluation of Pinellia tuber by LC-TOF/MS targeted to ephedrine. J Nat Med. 2021;75(3):692-698.

43. Cheng E, Hsiao R, Feliciano Z, et al. Taken to heart-arrhythmic potential of heart-leaf sida, a banned ephedrine alkaloid: a case report. Eur Heart J Case Report. 2022;6(1):ytac023.

44. Lindsay BD. Are serious adverse cardiovascular events an unintended consequence of the Dietary Supplement Health and Education Act of 1994? Mayo Clin Proc. 2002;77:7-9

45. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc. 2002;77:12-16.

46. Baker J, Zhang X, Boucher T, Keyler D. Investigation of quality in ephedrine-containing dietary supplements. Journal of Herbal Pharmacotherapy. 2003;3:5-17e

47. Liu YM and Sheu SJ. Determination of ephedrine alkaloids by capillary electrophoresis. J Chromatog. 1992;600:370-372.

48. Gurley BJ, Wang P, Gardner SF. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (ma-huang) as determined by high performance liquid chromatography. J Pharm Sci. 1998;87(12):1547-1553.

49. Chen WL, Tsai TH, Yang CC, Kuo TB. Acute effects of ephedra on autonomic nervous modulation in healthy young adults. Clin Pharmacol Ther. 2010;88(1):39-44.

50. Chen WL, Tsai TH, Yang CC, Kuo TB. Effects of ephedra on autonomic nervous modulation in healthy young adults. J Ethnopharmacol. 2010;130(3):563-568.

51. Dickson A. The Safety of Ephedra and Related Alkaloids. Available at https://www.clevelandclinicmeded.com/medicalpubs/pharmacy/marapr2003/ephedra.htm. Last accessed October 22, 2025.

52. Morgenstern LB, Viscoli CM, Kernan WN, et al. Use of Ephedra-containing products and risk for hemorrhagic stroke. Neurology. 2003;60:132-135.

53. Karch SB. Use of Ephedra-containing products and risk for hemorrhagic stroke. Neurology. 2003;61(5):724-725.

54. National Center for Complementary and Integrative Health. Ephedra. Available at https://www.nccih.nih.gov/health/ephedra. Last accessed October 22, 2025.

55. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med. 2000;343:1833-1838

56. Gugliotta G. FDA Takes Aim at Ephedra. Available at http://www.washingtonpost.com/archive/politics/2000/03/19/fda-takes-aim-at-ephedra/4ce534a7-d291-44ec-88a8-38e97ff27e3b/. Last accessed October 21, 2025.

57. Levisky JA, Karch SB, Bowerman DL, et al. False-positive RIA for methamphetamine following ingestion of an Ephedra-derived herbal product. J Anal Toxicol. 2003;27:123-124.

58. TRC Healthcare. Senna. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=652. Last accessed October 21, 2025.

59. National Toxicology Program. Toxicology study of senna (CAS No. 8013-11-4) in C57BL/6NTAC mice and toxicology and carcinogenesis study of senna in genetically modified C3B6.129F1/Tac-Trp53tm1Brd haploinsufficient mice (feed studies). Natl Toxicol Program Genet Modif Model Rep. 2012;(15):1-114.

60. TRC Healthcare. Castor Bean. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=897. Last accessed October 21, 2025.

61. Tunaru S, Althoff TF, Nusing RM, et al. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors. Proc Natl Acad Sci USA. 2012;109(23):9179-9184.

62. Davidson L, Rawat M, Stojanovski S, Chandrasekharan P. Natural drugs, not so natural effects: neonatal abstinence syndrome secondary to "kratom." J Neonatal Perinatal Med. 2019;12(1):109-112.

63. Joo JS, Ehrenpreis ED, Gonzalez L, et al. Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. J Clin Gastroenterol. 1998;26:283-286.

64. Nusko G, Schneider B, Schneider I, et al. Anthranoid laxative use is not a risk factor for colorectal neoplasia: results of a prospective case control study. Gut. 2000;46:651-655.

65. Müller-Lissner S: Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013;9(4): 391-401

66. Whorewell P, Lange R, Scarpignato C. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. Therap Adv Gastroenterol. 2024;17:17562848241249664.

67. Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100:232-242.

68. Goodwin AK, Brown PR, Jansen EE, et al. Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl). 2009;204(3):465-476.

69. TRC Healthcare. Gamma-hydroxybutyrate. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=950. Last accessed October 21, 2025.

70. Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen Pharmacol. 1992;23:1027-1034.

71. Mason P, Kerns II W. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med. 2002;9:730-39.

72. Schwartz RH, Milteer R, LeBeau MA. Drug-facilitated sexual assault ('date rape'). South Med J. 2000;93(6):558-591.

73. Khan JI, Kennedy TJ, Christian DR. Clandestine operations: synthetic methods, hazards, and safety. In: Basic Principles of Forensic Chemistry. Totowa, NJ: Humana Press; 2011.,.

74. Product information for Xyrem. Jazz Pharmaceuticals, Inc. Palo Alto, CA. April 2023.

75. Product information for Lumryz. Avadel CNS Pharmaceuticals, LLC. Chesterfield, MO. October 2024.

76. National Drug Intelligence Center. Information bulletin: GHB analogs; GBL, BD, GHV, and GVL.U.S. Department of Justice. Available at: https://www.justice.gov/archive/ndic/pubs1/1621/index.htm. Last accessed October 21, 2025.

77. van Noorden MS, Kamal RM, Dijkstra BA, Mauritz R, de Jong CA. A case series of pharmaceutical gamma-hydroxybutyrate in 3 patients with severe benzodiazepine-resistant gamma-hydroxybutyrate withdrawal in the hospital. Psychosomatics. 2015;56(4):404-409

78. Wolf CJH, Beurmanjer H, Dijkstra BAG, et al. Characterization of the GHB withdrawal syndrome. J Clin Med. 2021;10(11):2333.

79. TRC Healthcare. Phenibut. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=1184. Last accessed October 21, 2025.

80. Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and notropic drug. CNS Drug Rev. 2001;7(4):471-481.

81. Behmer Hansen RA, Behmer Hansen RT, Noureddine C. et al. Reasons for use and experiences of using phenibut, a mixed methods analysis of online reports. Am J Drug Alcohol Abuse. 2023;49(4):458-469.

82. Cohen PA, Ellison RR, Travis JC, Gaufberg SV, Gerona R. Quantity of phenibut in dietary supplements before and after FDA warnings. Clin Toxicol (Phila). 2022;60(4):486-488.

83. U.S. Food and Drug Administration. FDA Acts on Dietary Supplements Containing DMHA and Phenibut. Available at https://www.fda.gov/food/hfp-constituent-updates/fda-acts-dietary-supplements-containing-dmha-and-phenibut. Last accessed October 21, 2025.

84. Therapeutic Goods Administration. 2.3 Phenibut. In Scheduling Delegates' Interim Decisions and Invitation for Further Comment: ACCs/ACMS March and July 2017. Australian Government Department of Health. Available at https://www.tga.gov.au/resources/publication/scheduling-decisions-interim/scheduling-delegates-interim-decisions. Last accessed October 21, 2025.

85. Upmanis T, Sevostjanovs E, Zvejniece L, et al. Purchasing "nootropics" online: identification and quantification of ingredients in phenibut-containing products. Medicine. 2024;60(10):1561.

86. Graves JM, Dilley J, Kubsad S, Liebelt E. Notes from the field: phenibut exposures reported to poison centers - United States, 2009–2019. MMWR. 2020;69(35):1227-1228.

87. Arndt C, Gray TR. Phenibut, a GABAB agonist, detected in a fatality. J Anal Toxicol. 2021; [Epub ahead of print].

88. Gassaway MM, Rives ML, Kruegel AC, et al. The atypical antidepressant and neurorestorative agent tianeptine is a µ-opioid receptor agonist. Transl Psychiatry. 2014;4(7):e411.

89. Edinoff AN, Sall S, Beckman SP, et al. Tianeptine, an antidepressant with opioid agonist effects: pharmacology and abuse potential, a narrative review. Pain Ther. 2023;12(5):1121-1134.

90. TRC Healthcare. Tianeptine. Available at https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=1587. Last accessed October 21, 2025.

91. U.S. Food and Drug Administration. Tianeptine Products Linked to Serious Harm, Overdoses, Death. Available at https://www.fda.gov/consumers/consumer-updates/tianeptine-products-linked-serious-harm-overdoses-death. Last accessed October 21, 2025.

92. Hershey HL, Onyango EM, Durst K, et al. Tianeptine-involved emergency department visits, fatal overdoses, and substance seizures in Tennessee, 2021–2023. Drug Alcohol Depend Rep. 2024;12:100272.

93. Counts C, Spadaro A, Cerbini T, et al. An outbreak of synthetic cannabinoid-adulterated tianeptine products in New Jersey-Case series. Jour of Med Toxicol. 2025;21:253-259.

94. Summary of Product Characteristics Stablon: Tianeptine. Available at: https://www.servier.com.ve/sites/default/files/spc-pil/spc-stablon.pdf. Last accessed October 21, 2025.

95. Lucaj S, Leo RJ. Tianeptine sodium: a nootropic with potentially lethal consequences. Prim Care Companion CNS Disord. 2018;20(4).

96. Wolfson P, Hoffmann DL. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med. 2003;9:74-78.

97. Awad R, Arnason JT, Trudeau V, et al. Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties. Phytomedicine. 2003;10(8):640-649.

98. Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792-799.

99. TRC Healthcare. Kratom. Available at: https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=1513. Last accessed October 21, 2025.

100. U.S. Drug Enforcement Administration. Kratom. Available at https://www.dea.gov/sites/default/files/2025-01/Kratom-Drug-Fact-Sheet.pdf. Last accessed October 21, 2025.

101. Griffin OH, Webb ME. The scheduling of kratom and selective use of data. J Psychoactive Drugs. 2018;50(2):114-120.

102. Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. J Med Toxicol. 2016;12(4):341-349.

103. Singh D, Narayanan S, Vicknasingam B, et al. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol. 2017;32(3).

104. Coe MA, Pillitteri JL, Sembower MA, et al. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24-32.

105. Graves JM, Dilley JA, Terpak L, et al. Kratom exposures among older adults reported to U.S. poison centers, 2014–2019. J Am Geriatr Soc. 2021;69(8):2176-2184.

106. Griffin OH, Webb ME. The scheduling of kratom and selective use of data. J Psychoactive Drugs. 2017:1-7.

107. U.S. Food and Drug Administration. FDA Issues Warnings to Companies Selling Illegal, Unapproved Kratom Drug Products Marketed for Opioid Cessation, Pain Treatment. Available at https://www.fda.gov/news-events/press-announcements/fda-issues-warnings-companies-selling-illegal-unapproved-kratom-drug-products-marketed-opioid. Last accessed October 21, 2025.

108. Centers for Disease Control and Prevention. Multistate outbreak of Salmonella infections linked to kratom: 2018 Outbreaks. Available at https://www.cdc.gov/salmonella/kratom-02-18/index.html. Last accessed October 21, 2025.

109. Schwensohn C, Nsubuga J, Cronquist L, et al. A multiple-serotype outbreak of Salmonella infections linked to kratom, United States, 2017–2018. Foodborne Pathog Dis. 2022;19(9):648-653.

110. Mordor Intelligence. North America Dietary Supplement Market – Growth, Trends, and Forecast (2025–2030). Available at https://www.mordorintelligence.com/industry-reports/north-america-dietary-supplement-market. Last accessed October 21, 2025.

111. Kittirattanapaiboon P, Suttajit S, Junsirimongkol B, Likhitsathian S, Srisurapanont M. Suicide risk among Thai illicit drug users with and without mental/alcohol use disorders. Neuropsychiatr Dis Treat. 2014;10:453-458.

112. Muhammad BY, Abdullahi AD, Kadir, SS, Abdul Razak TB, Ahmed QU. In-utero effects of the crude ethanolic extract of the leaves of Mitragyna speciose on neural tube formation in rats. Asian J Exp Biol Sci. 2010;1(2):404-408.

113. Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Physician. 2018;64(2):121-122.